非酒精性脂肪性肝病谱系疾病状态转换概率:配对活检或影像学研究的系统评价与Meta分析
该系统评价与Meta分析检索1985至2020年多个数据库,纳入54项研究共26738例患者,评估成人非酒精性脂肪性肝病(NAFLD)中非酒精性脂肪肝(NAFL)、非酒精性脂肪性肝炎(NASH)及纤维化的进展与消退率。观察性研究中20%健康成人发生NAFL,21%脂肪肝患者NAFL消退;31%患者进展为NASH,29%NASH患者消退。结论认为进展为NASH较NASH消退更常见,纤维化进展率各基线分期相似,但晚期纤维化患者更易消退。
要点
- 观察性研究中20%健康成人发生NAFL,发生率4.8/100人年。
- 31%患者进展为NASH,29%NASH患者消退,进展较消退常见。
- 纤维化进展各期相似,但晚期纤维化患者较轻度纤维化更易消退。
核心结论
- Meta分析显示进展为NASH较NASH消退更常见。
- 纤维化进展率在各基线分期相似,但晚期纤维化患者较轻度纤维化更易消退。
研究设计与样本
- 系统评价与Meta分析,检索PubMed/Medline等5个数据库1985年至2020年文献。
- 纳入采用肝活检或影像学诊断NAFLD、随访≥48周的观察性研究和随机对照试验,共54项研究26738例患者。
- 发生率按每100人年计算,采用随机效应泊松分布模型合并,异质性用I2统计量评估。
主要发现
- 观察性研究中20%健康成人发生NAFL(发生率4.8/100人年),21%脂肪肝患者NAFL消退(发生率2.4/100人年),中位随访约4.5年。
- 31%患者进展为NASH(发生率7.4/100人年),中位4.7年;29%NASH患者消退(发生率5.1/100人年),中位3.5年。
- 纤维化进展1个分期的年数分别为F0 9.9年、F1 10.3年、F2 13.3年、F3 22.2年。
- 纤维化消退1个分期的年数分别为F4 21.3年、F3 12.5年、F2 20.4年、F1 40.0年。
- 随机对照试验估计的率高于观察性研究。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We conducted a meta-analysis to summarize the rates of progression to and regression of nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and fibrosis in adults with nonalcoholic fatty liver disease (NAFLD). METHODS: We searched PubMed/Medline and 4 other databases from 1985 through 2020. We included observational studies and randomized controlled trials in any language that used liver biopsy or imaging to diagnose NAFLD in adults with a follow-up period ≥48 weeks. Rates were calculated as incident cases per 100 person-years and pooled using the random-effects Poisson distribution model. Heterogeneity was assessed using the I2 statistic. RESULTS: We screened 9744 articles and included 54 studies involving 26,738 patients. Among observational studies, 20% of healthy adults developed NAFL (incidence rate, 4.8/100 person-years) while 21% of people with fatty liver had resolution of NAFL (incidence rate, 2.4/100 person-years) after a median of approximately 4.5 years. In addition, 31% of patients developed NASH after 4.7 years (incidence rate, 7.4/100 person-years), whereas in 29% of those with NASH, resolution occurred after a median of 3.5 years (incidence rate, 5.1/100 person-years). Time to progress by 1 fibrosis stage was 9.9, 10.3, 13.3, and 22.2 years for F0, F1, F2, and F3, respectively. Time to regress by 1 stage was 21.3, 12.5, 20.4, and 40.0 years for F4, F3, F2, and F1, respectively. Rates estimated from randomized controlled trials were higher than those from observational studies. CONCLUSIONS: In our meta-analysis, progression to NASH was more common than regression from NASH. Rates of fibrosis progression were similar across baseline stage, but patients with advanced fibrosis were more likely to regress than those with mild fibrosis.
引用
- Le P, Payne JY, Zhang L, et al. Disease State Transition Probabilities Across the Spectrum of NAFLD: A Systematic Review and Meta-Analysis of Paired Biopsy or Imaging Studies. Clin Gastroenterol Hepatol. 2022. PMID: 35933075. doi:10.1016/j.cgh.2022.07.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。